IV: $$$

Spectrum of Activity

General Information

Haematology/Oncology & HPCT patients with fever and neutropenia

EAP (Injection)

  • Nephrotoxicity (non-oliguric) - less common with once daily dosing; greater toxicity with longer duration and supratherapeutic trough levels; avoid concomitant nephrotoxins

  • Vestibulocochlear toxicity (irreversible) - audiology testing is recommended if prolonged or recurrent use, such as in Cystic Fibrosis

  • Can exacerbate neuromuscular blockade - e.g. contraindicated in patients with myasthenia gravis

  • Enhanced nephrotoxic effect with concomitant use of other nephrotoxins

  • Enhanced ototoxicity with loop diuretics (e.g. furosemide)

  • Non-depolarizing muscle relaxants may be potentiated

  • Calculate amikacin dose based on actual body weight unless patient weighs ≥125% of ideal body weight in which case dose is based on adjusted body weight

  • Dosage Guidelines for Haematology/Oncology and HPCT patients apply to children with normal renal function

  • 8A, 8B patients awaiting transplant should receive q24h aminoglycoside therapy when indicated for fever/infection